Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The new accounting date is to September 2025, changed from March, so the next full audited report is for 18 months to be announced in January 2026.</li>
<li>The trading-update on 4 November last week included a 12-month contribution from ABISS which was acquired on 9 September 2024.</li>
<li>RUA stated its growth strategy is to increase the scale of the medical device and component manufacturing, reduce customer concentration, develop royalties from Biomaterials, and break-even.</li>
</ul>


The new accounting date is to September 2025, changed from March, so the next full audited report is for 18 months to be announced in January 2026.
The trading-update on 4 November last week included a 12-month contribution from ABISS which was acquired on 9 September 2024.
RUA stated its growth strategy is to increase the scale of the medical device and component manufacturing, reduce customer concentration, develop royalties from Biomaterials, and break-even.


Hybridan Research: RUA Life Sciences: Journey to a Higher Value

United Kingdom

Rua Life Sciences PLC provides medical devices. The Company offers biomaterials, oft tissue patches, heart valve leaflets, and other related products. Rua Life Sciences serves customers in the United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00